Navigation Links
Velos Set to Clear 50 Percent Market Penetration of Large U.S. Clinical Research Sites by Year End
Date:8/7/2008

ghout the past few years and now includes 21 Top 25* U.S. centers. Clinical and Translational Science Award (CTSA) winners have chosen Velos by a wide margin versus all other vendors combined. Velos eResearch customers receive 47 percent of extramural clinical research funding from the National Institutes of Health -- also the largest such share for any commercial clinical trial management system. Most of these larger institutions are rolling out Velos eResearch across their healthcare systems and medical research programs. Founded in 1996, Velos is privately held with headquarters in Fremont, California. For more information, visit http://www.velos.com.

This press release may contain forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements.

* U.S. News and World Report 2008 America's Best Hospitals


'/>"/>
SOURCE Velos, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Velos to Develop Key System Interface for Clinical Research
2. Top Academic Medical Centers, Research Institutions, and Partners Gather, Share Experiences and Success Stories at Velos eResearch Annual Meeting
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Instrumentation Laboratory Receives FDA Clearance for HemosIL RecombiPlasTin 2G Assay
5. Rcadias COR Analyzer Family of Products Receives Second FDA Clearance
6. Two Point of Care Tests From Quest Diagnostics Receive FDA 510(k) Clearance
7. FDA Clears Advanced Test for Monitoring Metastatic Colorectal Cancer
8. BD Announces FDA 510(k) Clearance of Two-Hour Test to Identify Superbug in Patients with Positive Blood Cultures
9. Kingfisher Announces FDA 510(k) Clearance of Breakthrough KFH Energy for Chronic Pain Sufferers
10. Thermo Fisher Scientific Receives FDA Clearance for MRSA Test Medium
11. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Maxygen, Inc. Announces Extension of Dutch Auction Tender Offer 2Circassia Raises GBP15 Million ($25 Million) in Oversubscribed Investment Round 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 3FDNY Makes Largest First Responder Purchase of Masimo Rad 57 Pulse CO Oximeters to Improve Survival of Firefighters and Victims of Carbon Monoxide Poi 56362 1FDNY Makes Largest First Responder Purchase of Masimo Rad 57 Pulse CO Oximeters to Improve Survival of Firefighters and Victims of Carbon Monoxide Poi 56362 2FDNY Makes Largest First Responder Purchase of Masimo Rad 57 Pulse CO Oximeters to Improve Survival of Firefighters and Victims of Carbon Monoxide Poi 56362 3FDNY Makes Largest First Responder Purchase of Masimo Rad 57 Pulse CO Oximeters to Improve Survival of Firefighters and Victims of Carbon Monoxide Poi 56362 4Multiple Abstracts Related to KRYSTEXXA 28TM 29 Development and Treatment Failure Gout to be Presented at the 2009 ACR ARHP Annual Scientific Meeting 13887 1Multiple Abstracts Related to KRYSTEXXA 28TM 29 Development and Treatment Failure Gout to be Presented at the 2009 ACR ARHP Annual Scientific Meeting 13887 2Multiple Abstracts Related to KRYSTEXXA 28TM 29 Development and Treatment Failure Gout to be Presented at the 2009 ACR ARHP Annual Scientific Meeting 13887 3Multiple Abstracts Related to KRYSTEXXA 28TM 29 Development and Treatment Failure Gout to be Presented at the 2009 ACR ARHP Annual Scientific Meeting 13887 4Working Moms Vision Not Near Perfect 56357 1Working Moms Vision Not Near Perfect 56357 2Working Moms Vision Not Near Perfect 56357 3